Capivasertib was approved as a second-line treatment in November 2023 for use in patients with HR+/HER2-locally advanced or metastatic BC with one or more PIK3CA/AKT/PTEN alterations [19] based on results from the phase 3 CAPItello-291 trial (NCT04305496) [20]. This evidence concerns the gene ERBB2 and breast cancer.